Peripheral blood progenitor cells are now commonly used for hematologic reconstitution after myelosuppressive chemotherapy for hematologic and solid malignancies. The purpose of this study was to evaluate the activity of paclitaxel 170 mg/m 2 and cyclophosphamide 2 g/m 2 (CP) with filgrastim (human G-CSF) for mobilization of PBPCs as the first or second maneuver after failure with filgrastim alone. Sixty-four patients with stage II-IV breast cancer received (CP) followed by filgrastim (10 g/kg/day). In 35 (55%) this was the first maneuver while it was for salvage in 29 (45%) patients. The median number of aphereses was two (range, 1-7). In 83% of the patients apheresis was initiated on days 10-11 following chemotherapy. + cells/kg in only 45% (13/29) of cases vs 94.3% as first maneuver. CP followed by filgrastim is a safe and effective regimen for the mobilization of PBPCs in patients with breast cancer and shows significant activity in patients who failed to mobilize with filgrastim, suggesting a higher mobilization potential.
accelerate the tempo of engraftment compared to bone marrow cells, thereby reducing morbidity, mortality, support measures required and economic costs. [1] [2] [3] [4] In addition, PBPCs can be collected in an outpatient setting with minimal morbidity avoiding the operative procedure of BM harvest. Hematopoietic growth factors alone can provide an adequate yield of stem cells to ensure hematological reconstitution after HDC. Collection of PBPCs after CT followed by cytokines takes advantage of the additional mobilizing effect of the myelosuppressive drugs. The use of chemotherapy has been recognized to increase PBPC yields compared to cytokines alone, therefore requiring fewer apheresis procedures. 5, 6 In spite of the extensive experience acquired in this area, it is not known which is the best regimen to mobilize hematopoietic progenitor cells. Mobilization with disease-oriented chemotherapy together with cytokines may be also combine the advantage of antitumor activity with PBPC mobilization. 7, 8 Paclitaxel and cyclophosphamide are both active in breast cancer and share a similar pattern of hematological recovery. The value of a combination of paclitaxel and cyclophosphamide as a mobilization regimen in patients with ovarian and breast cancer has already been described. 9, 10 One of the problems associated with the use of PBPCs is the variability in the number of cells collected between patients, partly because of the amount of previous treatment. [11] [12] [13] [14] Moreover, cytokines by themselves will fail to mobilize stem cells in 10% of patients. 5, 11, 15 Some of these patients still will be salvaged adding chemotherapy, higher doses of growth factors or both, but the ideal salvage regimen is controversial. 16 Our report studies the efficacy of paclitaxel 170 mg/m 2 and cyclophosphamide 2 g/m 2 (CP) with filgrastim, and particularly analyzes its value as a salvage maneuver after failure to mobilization by filgrastim alone.
Patients and methods

Patients
Between November 1996 and January 1998 64 women with stage II-IV breast cancer underwent PBPC collection after paclitaxel 170 mg/m 2 and CP 2 g/m 2 followed by subcutaneous filgrastim. Thirty-five (55%) patients were mobilized in this fashion as first maneuver, and 29 (45%) after a prior, unsuccessful attempt with filgrastim 10 g/kg alone (45%) ( Table 1) . Thirty-two patients who had either bone marrow involvement or multiple skeletal metastasis were involved in a protocol for CD34 selection as a means of tumor purging and had CD34 positive enrichment of the PBPC production after collection using the Isolex 300i (Baxter Healthcare Corporation, Irvine, CA, USA). Patients could have received prior chemotherapy for metastatic disease. As part of this protocol, patients underwent initial PBPC mobilization with CP. Three additional patients with high risk primary breast cancer either stage II (one) or III (two) received CP as the initial mobilization regimen. These patients had mobilization with CP because of delays in obtaining insurance coverage and received chemotherapy because of the length of time since their last chemotherapy.
Patients who were initially mobilized with filgrastim but did not produce 2. + cell/kg within 3 days and had a falling PB CD34 + cell count were also considered mobilization failures and proceeded to CP mobilization. No patients received a second mobilization with filgrastim at either the same or an increased dose. Five of the women who received CP, as the second mobilization regimen had stage II disease and 24 (83%) had stage IV disease. The median number of chemotherapy cycles either adjuvantly and/or for metastatic disease was 10 (range, and eight (range, 3-24), for patients undergoing mobilization as a first or salvage maneuver, respectively.
Mobilization
On day 1 paclitaxel 170 mg/m 2 was diluted in 500 cc D5W in a glass container with a polyethylene-line tubing and a 0.22 m in-line filter and infused over 24 h intravenously. Patients were premedicated with dexamethasone 20 mg orally 12 and 6 h before paclitaxel and dexamethasone 20 mg i.v., diphenhydramine 50 mg i.v. and cimetidine 300 mg i.v. 20 min before paclitaxel administration. Cyclophosphamide 2.0 g/m 2 was given intravenously 1 h after the completion of the paclitaxel. Cyclophosphamide was infused over 1 h. All patients received MESNA for the prevention of hemorrhagic cystitis. The MESNA dose was 2.0 g/m 2 as equally divided administrations prior to infusion of CP and 4 and 8 h after. Following chemotherapy patients received filgrastim 10 g/kg/day subcutaneously. Patients also received ciprofloxacin, 500 mg three times a day as bacterial prophylaxis.
Collection and cryopreservation of PBPC
Following the administration of the chemotherapy and filgrastim, patients had complete blood counts measured every other day and began apheresis when the WBC count was at least 1.5 × 10 9 /ml. Daily apheresis procedures were performed using a Fenwall CS 3000 plus cell separator (Fenwall, Baxter Healthcare Corporation, Round Lake, IL, USA). Sixteen liters were processed per procedure, using continuous flow centrifugation at a flow rate of 70 ml/min. The target was to collect у5.0 × 10 6 CD34 + cells/kg, but attempts were made to collect a minimum of 2.5 × 10 6 cells/kg. The final product containing 10% DMSO and autologous plasma was frozen in a liquid nitrogen controlled-rate freezer and was maintained in the liquid phase of liquid nitrogen.
High-dose chemotherapy regimens
All but three patients received cisplatin, CP and BCNU (STAMP I) followed by PBPC infusion.
Cyclophosphamide, cisplatin and BCNU: Sixty-one patients received cyclophosphamide (1875 mg/m 2 /day) days −6 to −4, cisplatin (165 mg/m 2 ) continuous i.v. infusion days −6 to −4, and BCNU (600 mg/m 2 ) on day −3, as follows. Actual body weight was used to calculate the therapeutic doses of all agents unless the actual body weight was 20% greater than the ideal body weight. In the event that the actual body weight was 20% greater the average of the ideal and actual body weight was used to calculate the therapeutic doses. PBPCs were reinfused 3 days after the completion of the regimen. Patients received fil-grastim 5 g/kg/day s.c. starting 3 h after the completion of the PBPC infusion. Patients were discharged from hospital after the PBPBC infusion and followed daily in the outpatient transplantation clinic. 
Measurement of CD34
+ cells
Peripheral blood was analyzed prior to apheresis for CD34 + cell counts using flow cytometry. An aliquot of each apheresis product was collected and the CD34 + cell content measured. CD34
+ cell enumeration was performed as previously described. 17 
Statistics
Statistical comparisons were made with SPSS software. The Mann-Whitney, Wilcoxon and Kruskal-Wallis tests were used for non-parametric analyses. Proportions were compared using chi-square or Fisher's exact method, as appropriate. Multivariate associations were assessed using a multiple regression model. Factors were included in a stepwise manner. Time to collect at least 2.5 and 5 × 10 6
CD34
+ cells and time to initiate apheresis were estimated using the product-limit method according to Kaplan and Meier and comparisons made by Breslow test.
Results
PBPC collections
PBPC collection was initiated when the WBC was Ͼ1.5 × 10 9 /l. The median day for starting apheresis was day 10 after receiving the mobilizing chemotherapy (range, 7-17). The date of initiating leukapheresis following CP was very consistent, with more than 80% of patients starting the collections on days 10 or 11. There was no statistically significant difference in the day to start the apheresis between the two groups. On the first day of collection the median WBC and CD34 + cell counts were 4.65 × + cells/l and the CD34 + cells per kilogram in the apheresis collection (r = 0.82, P Ͻ 0.001). All patients reached a minimum collection of 2 × 10 6 CD34 + cells/kg. Sixty-two per cent of patients collected у2.5 × 10 6 and 52% у5 × 10 6 CD34 + cells/kg with the first apheresis (Figures 1 and 2 ). The number of CD34 + cells collected on the first day of apheresis was superior to the second or subsequent days. Comparisons between the primary mobilization and salvage mobilization groups are shown in Table 2 . There was a significant difference in the number of CD34
+ cells collected between the group that had CP as + cells/kg in patients receiving CP as salvage, compared with 16.93 × 10 6 CD34 + cells/kg when CP was used as first mobilization (P Ͻ 0.001). Four patients in the salvage group (13.7%) did not achieve the target number of 2.5 × 10 6 and 16 did not collect 5 × 10 6 , vs 0 and 2, respectively, in the initial mobilization group (P Ͻ 0.001).
Analysis of prognostic factors of mobilization
Patients' characteristics were analyzed for factors that influenced CD34
+ cell collection including age, stage of disease at the time of HDC, bone marrow involvement, number of prior regimens and chemotherapy cycles, prior radiotherapy, and order of mobilization. Only the last was associated with worse PBPC yields and was a predictive factor for failure to collect at least 5 × 10 6 CD34 + cells (Table 3) .
Engraftment kinetics after PBPCT
All but one patient who progressed during induction proceeded to high-dose chemotherapy and PBPCT. In 25 patients who received the selected CD34 + PBPC, the median day to reach an absolute neutrophil count of 0.5 × 10 9 /l and unsustained platelet count of 20 × 10 9 /l were /l were 9 (range, 8-11) and 16 (range, 11-60), respectively, after the PBPC infusion.
Toxicity of the regimen
Nine patients (14%) required admission because of febrile neutropenia (two catheter infections caused by S. epidermidis and by S. aureus, one patient presented with sinusitis and bronchitis and six patients had no documented bacteriological or clinical infection). No differences were observed between first and salvage mobilizations. No procedurerelated deaths occurred.
Discussion
Paclitaxel is now a well-established agent in the treatment of breast cancer, with significant activity even in doxorubicin-resistant tumors. 18 Paclitaxel causes less thrombocytopenia, does not have cumulative hematological toxicity and seems to spare the pool of primitive stem cells. 19 These factors make it an optimal tool to mobilize PBPCs in breast cancer patients. Paclitaxel has been used alone 20 or combined with either CP 9, 10, [21] [22] [23] or epirubicin 24, 25 for PBPC mobilization. CP has been tested with different schedules and doses, ranging for paclitaxel between 150-300 mg/m + cells/kg, as our results and others confirm. 10 CP also fulfilled another important requirement of a mobilization protocol, namely, predictable timing eliminating one of the criticisms of the use of chemotherapy as mobilization. This is influenced by the amount of previous chemotherapy and radiation treatment. CP accomplishes both safe and predictable mobilization in our poor prognostic group for mobilization. In addition, leukapheresis could be started on day 10 or 11 in 90% of patients as first attempt.
There is increasing evidence for faster recovery with higher doses of PBPCs infused. 15, 26, 27 This emphasizes the practical importance of effective mobilization in breast cancer patients in order to improve the CD34 + cell yields. 5, [11] [12] [13] [14] However, even with no or limited prior antineoplastic treatment, the number of PBPCs collected is variable among patients and 10% of them will fail to mobilize successfully. There is no agreement on the best regimen after initial failure to mobilize PBPCs by cytokines. Higher doses of filgrastim, cocktails of growth factors or chemotherapy and growth factors provided mobilization rates below 50%. 16 In our series, CP successfully salvaged the 29 patients who failed a first mobilization with filgrastim alone. These results are more important if we consider the adverse prognostic factors for mobilization exhibited in our series, such as a large amount of prior chemotherapy extensive bone disease, marrow involvement and prior radiotherapy. 5, [11] [12] [13] [14] 23 Interestingly, none of these factors were significantly worse in salvage mobilizations than in patients mobilized as first attempt. With initial CP in the current study, all but two patients reached the target of 5 × 10 6
CD34
+ cells/kg with a median of two (1-7) collections, as compared with 13/29 patients who received salvage CP. The yield of CD34 + cells and average CD34 + cells/kg/apheresis collected were significantly lower (P Ͻ 0.001) in the salvage patients. Moreover, the only prognostic factor associated with the number of CD34 + cells collected per apheresis after CP was the failure to mobilize adequate PBPCs with filgrastim alone. This information suggests that various factors affect the mobilization of PBPC whether the patients received growth factor alone or CP plus growth factor. Because of the success of this regimen for patients on our CD34
+ cell selection protocol we elected to use the CP mobilization rather than a second course of higher dose filgrastim. We were successful in collecting an adequate PBPC product in all patients salvaged with this regimen. The PBPC product was able to provide a rapid hematological recovery after transplant in all patients.
We have used a lower dose of CP than was originally reported for mobilization with paclitaxel and CP. 5 There were no episodes of hematuria associated with our regimen and the incidence of febrile neutropenia (14%) was lower than reported with CP (4 g/m 2 ) and paclitaxel (170 mg/m 2 ), 5 although this may have been related to the use of MESNA and prophylactic antibiotics during the neutropenic period.
In summary, CP is a highly effective method for mobilizing PBPCs, both as initial approach and as a salvage maneuver after failure to yield adequate PBPC product with filgrastim alone. It provided a sufficient number of hematopoietic progenitor cells to support HDC in all patients, suggesting a higher efficacy of CP plus filgrastim over filgrastim alone.
